Related Experiment Video

Updated: Aug 17, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Chemokine receptors and their antagonists in allergic lung disease

T N Wells1, A E Proudfoot

  • 1Serono Pharmaceutical Research Institute, Geneva, Switzerland. tim.wells@serono.com

Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|August 18, 1999
PubMed

Insights

Chemokines and their receptors guide leukocyte movement. Targeting chemokine receptors offers a promising strategy for selectively reducing inflammation without causing widespread immune suppression, with potential applications in allergic diseases.

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Leukocyte trafficking is regulated by cytokines and lipid mediators.
  • Chemokines, a family of small cytokines, play a key role in inflammation.
  • Chemokines act via seven-transmembrane spanning G-protein coupled receptors.

Purpose of the Study:

  • To review the current understanding of chemokine receptors.
  • To explore the therapeutic potential of targeting chemokine receptors.
  • To assess the clinical utility of chemokine receptor antagonists.

Main Methods:

  • Review of current literature on chemokine receptors.
  • Analysis of data from animal studies on chemokine antagonists.
  • Evaluation of clinical data in allergic diseases.

Main Results:

  • Chemokine receptor expression patterns influence cell recruitment to inflammatory sites.
  • Selective antagonism of chemokine receptors may down-regulate specific cell types.
  • Protein chemokine antagonists show potential in treating allergic diseases.

Conclusions:

  • Targeting chemokine receptors offers a selective approach to managing inflammation.
  • Chemokine receptor antagonists represent a promising therapeutic class.
  • Further clinical studies are warranted to validate therapeutic potential.

More Related Videos

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration07:03

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration

Published on: May 4, 2017

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...